Printer Friendly

RIBI IMMUNOCHEM REPORTS 1992 FIRST-QUARTER FINANCIAL RESULTS

 RIBI IMMUNOCHEM REPORTS 1992 FIRST-QUARTER FINANCIAL RESULTS
 HAMILTON, Mont., April 29 /PRNewswire/ -- Ribi ImmunoChem Research Inc. (NASDAQ: RIBI) announced today its financial results for the first quarter ended March 31, 1992.
 Total revenues for the first quarter increased 33 percent as a result of higher investment income and higher sales, achieving $408,530, as compared to $307,289 for the comparable period in 1991. Sales for the first quarter increased 6 percent, achieving $245,652, as compared to $232,652 in the comparable period in 1991.
 The net loss for the first quarter was $932,905, or 8 cents per share, compared to a net loss of $661,176, or 7 cents per share for the first quarter of 1991.
 "The net loss positively reflects our aggressive spending on product research and human clinical development made possible by cash infusions totaling $9.24 million in 1991 and approximately $11 million reported in April 1992," said Robert E. Ivy, chief executive officer, presidentand chairman. "Our cash position at the end of the first quarter of 1992 was more than 200 percent greater than at the end of the first quarter of 1991. We are using the $20 million raised in 1991 and 1992 to accelerate our pivotal Phase III controlled study of MELACINE(R) melanoma theraccine and to expand the clinical testing of MPL(R) immunostimulant to prevent or ameliorate sepsis and septic shock and to modulate organ reperfusion injury."
 RIBI IMMUNOCHEM RESEARCH INC.
 SUMMARY OF OPERATIONS
 (Unaudited)
 Three Months Ended March 31: 1992 1991
 Revenues:
 Sales $ 245,652 $ 232,652
 Investment and other 162,878 74,637
 Total 408,530 307,289
 Costs and expenses 1,341,435 968,465
 Net loss $ (932,905) $ (661,176)
 Loss per common share $ (0.08) $ (0.07)
 Average number of shares outstanding 12,122,073 8,953,593
 CONDENSED BALANCE SHEETS
 March 31, Dec. 31,
 1992 1991
 (unaudited)
 Current assets, principally cash and
 short-term investments $10,708,941 $11,061,751
 Property, plant and equipment, net 3,780,749 3,775,658
 Other assets, net 484,537 441,443
 Total $14,974,227 $15,278,852
 Current liabilities $ 450,227 $ 412,514
 Long-term debt -- --
 Shareholders' equity 14,524,000 14,866,338
 Total $14,974,227 $15,278,852
 -0- 4/29/92
 /CONTACT: Vern D. Child or Jeffrey S. McDowell of Ribi ImmunoChem Research, 406-363-6214/
 (RIBI) CO: Ribi ImmunoChem Research Inc. ST: Montana IN: MTC SU: ERN


TS-SC -- SE006 -- 4202 04/29/92 09:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:414
Previous Article:CYTOGEN PROMOTES DR. ROBERT MAGUIRE TO VICE PRESIDENT
Next Article:GLAXO DONATION TO FIGHT TB OUTBREAK IN U.S.


Related Articles
RIBI IMMUNOCHEM REPORTS 1991 FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS 1992 SECOND-QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS 1992 THIRD-QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS 1992 FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS FIRST-QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS SECOND QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS THIRD QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS 1993 FINANCIAL RESULTS
RIBI IMMUNOCHEM REPORTS 1994 FIRST QUARTER FINANCIAL RESULTS
Ribi Reports Q1 1998 Sales Up 310% Over Q1 1997

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters